loading
loading
Search fieldHome page Seeking Alpha - Power to InvestorsSearch for Symbols, analysts, keywordsAbout PremiumCreate free accountLog in Earnings News BioMarin Q3 financial results to see IPR&D expense impact of $283M Oct 06, 2026, 6:28 PM ETBioMarin Pharmaceutical Inc. (BMRN) StockBy : Jonathan Block, SA News Editor BioMarin Pharmaceutical (BMRN) said that it would incur an acquired in-process research and development (IPR&D) expense of $283M for Q3. As a result, GAAP and non-GAAP diluted EPS for the quarter will be negatively impacted by $1.50. The non-GAAP diluted EPS estimate for the quarter is $1.25. To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our feedback forum. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. Search fieldEntering text into the input field will update the search result below Recommended For You
document fetched 2026-10-07 02:56 · canonical https://seekingalpha.com/news/4650778-biomarin-q3-financial-results-see-ipr-and-d-expense-impact-283m?feed_item_type=news